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Ebola Virus Disease (EVD) is the most prominent example of filovirus disease but despite being characterized 
as a Category A Priority Pathogen by NIH/NIAID over a decade ago, it lacked public and private research 
resources due to the absence of a commercial market. Transmission from wild animals into the human 
population typically causes outbreaks of limited scale in endemic areas located in the forested regions of Central 
Africa and the Philippines (for Reston ebolavirus), therefore other public health threats garnered more attention. 
This changed when a Zaire Ebolavirus (EBOV) outbreak of increasing size in several West African countries 
started to reveal the true epidemic potential that filovirus infections can have when entering an urban setting in a 
highly mobile society. Despite significant progress with the clinical development of several EBOV vaccine 
candidates during and after the West African outbreak, no EBOV specific therapeutics and vaccines have yet 
received regulatory approval. Additional research is needed in particular on understanding the mechanism of 
protection and defining immune correlates of protection for Ebola and other filovirus vaccines.   
 
For our multivalent filovirus vaccine candidate, we have produced soluble recombinant filovirus glycoproteins 
(GP) from EBOV, Marburg marburgvirus (MARV) and Sudan ebolavirus (SUDV) using the Drosophila S2 cell 
expression system. The immunogenicity of highly purified recombinant subunits and admixtures formulated with 
or without clinically relevant adjuvants was evaluated in mice, guinea pigs and macaques. Strong antigen-
specific IgG titers as well as virus neutralizing titers were observed after administering two or three doses of 
adjuvanted formulations. In mice and non-human primates subunit proteins were also shown to elicit cell 
mediated immune responses. Analysis of secreted cytokines in batch-cultured, antigen-stimulated splenocytes 
or PBMC’s demonstrated antigen-induced Th1 and Th2 type responses. Recombinant vaccine candidates were 
tested successfully for protection in the mouse model of EBOV. Further studies allowed us to demonstrate that 
both humoral and cell-mediated immunity are elicited and can mediate protection. Additional immunogenicity 
and efficacy studies in guinea pigs were focused on optimized antigen dosing, antigenic balance and 
adjuvantation. Multiple formulations consistently produced strong antibody responses and demonstrated 100% 
protective efficacy in the EBOV guinea pig model.  
 
Results from studies in two species of non-human primates demonstrate that vaccination with formulations of 
recombinant EBOV subunits and an emulsion-based adjuvant consistently produces high anti-EBOV IgG and 
virus neutralizing titers. Such vaccination prevents viremia subsequent to live virus challenge and protects 
animals from terminal EBOV disease. These studies suggest that we have defined a viable Ebola virus vaccine 
candidate based on non-replicating viral subunits.  In addition to updates on efficacy testing against EBOV and 
MARV, we will discuss current formulation optimization efforts in our laboratory including thermostabilization of 
recombinant subunits as well as defining correlates of protection. These are prerequisites to enable efficient 
clinical development of a monovalent vaccine candidate for protection against EVD and a multivalent, 
recombinant subunit vaccine with protective efficacy against EBOV, SUDV and MARV infection.  
Recently we have also demonstrated the applicability of our vaccine platform for the rapid development of 
vaccines against emerging diseases with a focus on Zika virus (ZIKV), a flavivirus, where we were able to 
demonstrate efficacy in mice and cynomolgus macaques within approximately 13 months from designing the 
synthetic gene for antigen expression.  While a completely different disease from EVD, the recent outbreak of 
ZIKV in the Americas provided a similar challenge as no vaccine development efforts have been conducted prior 
to 2016 and an increasing body of evidence suggests that rather than causing a typical, mild form of disease as 
previously reported, ZIKV infections can cause neurological sequelae as well as fetal and infant malformations.   
 
These results demonstrate that the insect cell expression system can be used to rapidly and efficiently produce 
recombinant viral subunits from a variety of pathogenic viruses that are highly immunogenic in multiple animal 
species and are capable of providing effective vaccine protection against live virus challenge. 
